Textbook of Personalized Medicine - Second Edition [2015]

725

defi nition , 580

and functional foods , 581–582

personalized medicine , 582–583

vitamin D and Ca supplementation , 581

personalized diet prescription , 583–584

and proteomics , 583

O
Obamacare , 708
O f fi ce of Personalized Healthcare (OPH) , 604
Off-label prescription , 630
Oligodendroglial tumors (OTs) , 288–289
Omics techniques , 19, 173, 409–410, 574
Oncoproteomics , 261–262
OncoTrack , 342
Oncotype DX™ , 308–309, 314, 341, 672, 688
OncoVAX ® , 243, 252
OnkoMatch™ tumor genotyping , 210
Ontario Institute for Cancer Research (OICR) ,
368, 644–646
Optical Mapping™ , 51
Oral antidiabetic drugs (OADs) , 566
Oregon Health and Science University
(OHSU) , 624
Organ transplantation
anti-rejection medications , 560
cardiac , 559–560
immunological biomarkers , 561–563
immunosuppressent therapies , 560–561
kidney , 558–559
Oropharyngeal squamous cell carcinomas
(OPSCC) , 326
Osteoporosis , 572, 595
Ovarian cancer management , 318
cancer stem cells , 323
chemotherapy , 319–320
CLOVAR model , 320
early diagnosis , 319
hematogenous metastasis , 324
rapamycin, Akt signaling , 322
recurrence and drug-resistance
ChemoFX assay , 321
HGSC , 321, 322
quantitative RT-PCR , 322
Yale apoptosis assay , 321
Vynfi nit ® , PROC , 324–325
O V A 1 ® test , 319

P
Paclitaxel , 116, 303, 505–506
Pancreatic cancer
biomarkers of , 358–359

and gemcitabine delivery , 359–360

histone modifi cations , 359

Pancreatic ductal adenocarcinoma (PDAC) ,

359–360

Panitumumab , 83, 138, 340, 670

Parkinson disease (PD) , 601

characteristics , 421

cloning , 192

drug targets , 423

entacapone , 421

personalized cell therapy , 424

pharmacogenetics, role of , 423

whole exome sequencing , 422

Partial least-squares discriminate analysis

(PLS-DA) , 174

Partners Personalized Medicine , 623–624

Patents , 663–664

Patient-Centered Outcomes Research Institute

(PCORI) , 631

PDAC. See Pancreatic ductal adenocarcinoma

(PDAC)

PeaceHealth , 622

Personal Genome Project (PGP) , 44, 693–694

Personalized analysis of rearranged ends

(PARE) , 222

Personalized glucose advisory system

(PGASystem) , 565

Personalized medicine , 20

advances in , 704–705

advantages of , 651–652

bioinformatics, role of ( see Bioinformatics)

biological therapies ( see Biological

therapies)

biomarkers ( see Biomarkers)

biotechnology companies, role of , 597

in Canada ( see Canada, personalized

medicine)

cancer therapy ( see Cancer therapy)

and CER , 704

connected health and , 699

vs. conventional medicines , 20–21

defi nition of , 1–3

diseases reclassifi cation , 31

economics of ( see Economics,

personalized medicine)

ethical aspects of ( see Ethics)

in Europe ( see European Union (EU),

personalized medicine)

evidence-based medicine , 21

evolution of , 699, 701

genetic banking systems and databases

( see Biobanks)

genetic disorders ( see Genetic disorders)

healthcare organizations, role of , 628

Index